Ribo Newsroom

Ribo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillation

Ribo Appoints CMO and CBO to Empower Global R&D and Partnerships

Ribo expands beyond the liver with RiboPepSTAR™ – enabling targeted siRNA delivery to multiple organs

Ribo has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.

Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.

Ribo entered into an exclusive worldwide license agreement with Madrigal for six pre-clinical siRNA programs for the treatment of MASH.